4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity

A compound of formula (I):

• wherein:
• R1 is halo, cyano, C1-3alkyl or C1-3alkoxy;
• p is 0-2;
• wherein the values of R1 may be the same or different;
• R2 is C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl, C3-6cycloalkylC1-3alkyl, a heterocyclyl or heterocyclylC1-3 alkyl;
• wherein R2 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;
• and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;
• R3 is hydrogen, halo or cyano;
• R4 is C1-6alkyl or C1-6alkoxyC1-6alkyl;
• R5 is substituted methyl, optionally substituted C2-6alkyl, or optionally substituted C2-6alkenyl;
• wherein said substituents are selected from one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;
• or a pharmaceutically acceptable salt thereof;
• provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-isopropyl-imidazol-5-yl )-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[N-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine;
• 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(N-cyclopropylsulphamoyl) anilino]pyrimidine;
• 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(N-cyclobutyl-sulphamoyl) anilino]pyrimidine;
• or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl) sulphamoyl]anilino}pyrimidine.